Journal of Clinical Endocrinology & Metabolism, Vol 77, 478-483, Copyright © 1993 by Endocrine Society

ARTICLES

Factors determining glucose tolerance in patients with thalassemia major

K Dmochowski, DT Finegood, W Francombe, B Tyler and B Zinman
Department of Medicine, University of Toronto, Ontario, Canada.

To better understand the pathophysiology of glucose intolerance secondary to iron overload in patients with thalassemia major, we performed tolbutamide-modified frequently sampled iv glucose tolerance tests (FSIGTs) in 10 thalassemic patients (6 males and 4 females; 21.7 +/- 1.2 yr old; body mass index, 19.7 +/- 0.6 kg/m2) and 10 healthy controls (5 males and 5 females; 22.4 +/- 1.3 yr; body mass index, 20.6 +/- 0.5 kg/m2). Insulin secretion and action were quantified by application of the minimal model of glucose kinetics and the combined model of insulin and C-peptide kinetics to the FSIGT data. The insulin sensitivity index was significantly lower in thalassemia patients [72 +/- 12 min-1(nmol/mL)] compared to controls [158 +/- 21 min-1(nmol/mL); P = 0.0026]. The integrated insulin response during the FSIGT was significantly greater in thalassemia patients than in controls after tolbutamide injection (P = 0.042). The difference in insulin levels was apparently due to reduced hepatic insulin extraction in thalassemia (78 +/- 2% vs. 68 +/- 3%; P = 0.0251). Seven of the 10 thalassemia patients were studied prospectively at 6-month intervals for 6-12 months. Repeated measures analysis of variance indicated that across a 6-month interval, there was a decrease in the total integrated insulin response (P = 0.002), with no change in insulin sensitivity (P = 0.86). In conclusion, patients with thalassemia major have significant insulin resistance, which may be compensated for by an elevated circulating insulin level. The elevated insulin level in response to tolbutamide appears to be due to reduced hepatic extraction of insulin and not to an enhanced insulin secretory response. Over time, patients with thalassemia experience a reduction in their circulating insulin levels. Persistent insulin resistance along with a progressive reduction in circulating insulin levels may lead to glucose intolerance and diabetes mellitus, which have a high prevalence in patients with thalassemia major.

This article has been cited by other articles:

				S. Swaminathan, V. A. Fonseca, M. G. Alam, and S. V. Shah The Role of Iron in Diabetes and Its Complications Diabetes Care, July 1, 2007; 30(7): 1926 - 1933. [Full Text] [PDF]

				M. L. Jehn, E. Guallar, J. M. Clark, D. Couper, B. B. Duncan, C. M. Ballantyne, R. C. Hoogeveen, Z. L. Harris, and J. S. Pankow A Prospective Study of Plasma Ferritin Level and Incident Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study Am. J. Epidemiol., May 1, 2007; 165(9): 1047 - 1054. [Abstract] [Full Text] [PDF]

				J. M. Fernandez-Real, A. Lopez-Bermejo, and W. Ricart Iron Stores, Blood Donation, and Insulin Sensitivity and Secretion Clin. Chem., July 1, 2005; 51(7): 1201 - 1205. [Abstract] [Full Text] [PDF]

				J R Porter and T G Barrett Acquired non-type 1 diabetes in childhood: subtypes, diagnosis, and management Arch. Dis. Child., December 1, 2004; 89(12): 1138 - 1144. [Abstract] [Full Text] [PDF]

				J. C.N. Chan, N. M.S. Wat, W.-Y. So, K. S.L. Lam, C.-T. Chua, K.-S. Wong, Z. Morad, T. Z. Dickson, D. Hille, Z. Zhang, et al. Renin Angiotensin Aldosterone System Blockade and Renal Disease in Patients With Type 2 Diabetes: An Asian perspective from the RENAAL study Diabetes Care, April 1, 2004; 27(4): 874 - 879. [Abstract] [Full Text] [PDF]

				J. M. Fernandez-Real, A. Lopez-Bermejo, and W. Ricart Cross-Talk Between Iron Metabolism and Diabetes Diabetes, August 1, 2002; 51(8): 2348 - 2354. [Abstract] [Full Text] [PDF]

				J. M. Fernandez-Real, G. Penarroja, A. Castro, F. Garcia-Bragado, I. Hernandez-Aguado, and W. Ricart Blood Letting in High-Ferritin Type 2 Diabetes : Effects on Insulin Sensitivity and {beta}-Cell Function Diabetes, April 1, 2002; 51(4): 1000 - 1004. [Abstract] [Full Text] [PDF]

				J. P.S. Chern, K.-H. Lin, M.-Y. Lu, D.-T. Lin, K.-S. Lin, J.-D. Chen, and C.-C. Fu Abnormal Glucose Tolerance in Transfusion-Dependent {beta}-Thalassemic Patients Diabetes Care, May 1, 2001; 24(5): 850 - 854. [Abstract] [Full Text]

				N. F. Olivieri and G. M. Brittenham Iron-Chelating Therapy and the Treatment of Thalassemia Blood, February 1, 1997; 89(3): 739 - 761. [Full Text] [PDF]